We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Amino Acids Can Predict CV Disease Risk in Women

By LabMedica International staff writers
Posted on 16 Apr 2018
Results of a recent study supported the hypothesis that plasma BCAAs (branched-chain amino acids) were positively associated with cardiovascular disease (CVD) risk and were linked to an intermediate diagnosis of type II diabetes (T2D).

A branched-chain amino acid (BCAA) is an amino acid having aliphatic side-chains with a branch (a central carbon atom bound to three or more carbon atoms). More...
Among the amino acids found in proteins, there are three BCAAs: leucine, isoleucine, and valine. These three BCAAs are among the nine essential amino acids for humans, accounting for 35% of the essential amino acids in muscle proteins and 40% of the preformed amino acids required by mammals.

Circulating branched-chain amino acids (isoleucine, leucine, and valine) are strong predictors of type II diabetes mellitus (T2D), but their association with cardiovascular disease (CVD) is uncertain. To determine if BCAAs have a role in CVD, investigators at Brigham and Women's Hospital (Boston, MA, USA) measured BCAA levels in blood samples using NMR spectrometry. Of the more than 27,000 women studied, 2,207 experienced a cardiovascular event over the 18-year follow up period.

BCAAs were found to be positively associated with CVD at a degree comparable to LDL-C (low-density lipoprotein cholesterol). BCAAs were associated with coronary events (myocardial infarction, revascularization, and borderline significant association with stroke). The BCAA-CVD association was greater among women who developed T2D before CVD versus women without T2D. Adjusting for LDL-C, an established CVD risk factor, did not attenuate these findings; however, adjusting for HbA1c (glycosylated hemoglobin) and insulin resistance eliminated the associations of BCAAs with CVD.

"We examined more than 27,000 women in the Women's Health Study and found that a one-time measurement of branched chain amino acids in the blood stream - a test that now can be easily done - predicted future risk of cardiovascular events to the same extent and independent of LDL cholesterol and other risk factors," said senior author Dr. Samia Mora, a researcher at the center for lipid metabolomics at Brigham and Women's Hospital. "This was particularly so for women who developed type II diabetes prior to their cardiovascular disease."

The work was published in the March 23, 2018, online edition of the journal Circulation: Genomic and Precision Medicine.

Related Links:
Brigham and Women's Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The integration with FlexLab X brings the Panther System into fully tracked automation environments to increase capacity, traceability, and workflow efficiency (Photo courtesy of Hologic)

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe

Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.